217 related articles for article (PubMed ID: 10760436)
1. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
Amorino GP; Freeman ML; Carbone DP; Lebwohl DE; Choy H
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):399-405. PubMed ID: 10760436
[TBL] [Abstract][Full Text] [Related]
2. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
5. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
6. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
7. Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin.
Skov K; MacPhail S
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):221-5. PubMed ID: 1991682
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy.
Amorino GP; Mohr PJ; Hercules SK; Pyo H; Choy H
Cancer Chemother Pharmacol; 2000; 46(5):423-6. PubMed ID: 11127948
[TBL] [Abstract][Full Text] [Related]
9. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
10. Oral platinum analogue JM216, a radiosensitizer in oxic murine cells.
van de Vaart PJ; Klaren HM; Hofland I; Begg AC
Int J Radiat Biol; 1997 Dec; 72(6):675-83. PubMed ID: 9416790
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer.
Amorino GP; Hercules SK; Mohr PJ; Pyo H; Choy H
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):503-9. PubMed ID: 10802379
[TBL] [Abstract][Full Text] [Related]
12. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells.
O'Hara JA; Douple EB; Richmond RC
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1419-22. PubMed ID: 3531116
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
15. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
17. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
18. The radiomimetic properties of a platinum drug.
Barot HA; Laverick M; Nias AH
Br J Radiol; 1985 Jan; 58(685):51-62. PubMed ID: 3840711
[TBL] [Abstract][Full Text] [Related]
19. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro.
Amorino GP; Hamilton VM; Choy H
Radiat Oncol Investig; 1999; 7(6):343-52. PubMed ID: 10644057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]